Cellular screens

Our cellular screening platform is used either to:

• Select the most active compounds to be used in vivo. The first step is to select the suitable cell line based on target expression and indication. Screening of hundreds of compounds leads to the selection of the most active compounds.
• Select the models to be used in vivo. A panel of cell lines within a specific indication or representing a panel of indications is treated with a reduced number of compounds. The most sensitive cell lines are subsequently grafted in mice for the in vivo evaluation of the lead compounds.

We have a bank of more than 300 cell lines used for cytotoxicity assays (e.g. MTS, SRB, BrdU), clonogenicity assays and mechanistic assays (e.g. apoptosis and cell cycle analysis).

Our screening platform is also used to perform in vitro combination studies to study the effect between your compounds with or without standard-of-care agents (targeted agents, chemotherapeutics or radiotherapy). These in vitro combination studies can be used to select tumor indication, treatment sequences and the active compound concentrations that will guide the use of the combinations in vivo.

Our strategic alliances enable us to conduct in vitro studies using a unique panel of cell lines derived from primary tumors (Ludwig Institute and Curie Institute). We also have access to fresh primary hematological samples collected from volunteers at the Dijon Anticancer Center (Georges-François Leclerc Center - CGFL) to evaluate the effect of the treatment ex vivo.

We have developed a know how to evaluate the antitumor activity of your compounds using ⁵¹Cr release assays (ADCC, CDC) and mechanistic assays (apoptosis…) against the most relevant tumor samples: fresh primary samples directly obtained from patients.